News

EXO Biologics is pleased to announce 𝘁𝘄𝗼 𝗻𝗲𝘄 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 advancing extracellular vesicle (EV) therapeutics toward clinical development.

The first project is 𝗥𝗘𝗩𝗜𝗩𝗘-𝗣𝗗 – 𝗥𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗘𝘅𝘁𝗿𝗮𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗩𝗲𝘀𝗶𝗰𝗹𝗲𝘀 𝗶𝗻 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲, supported by the Olav Thon Foundation (Norway). The consortium has been awarded NOK 16 million in funding over four years (approximately €1.4 million) to develop EV-based approaches targeting neuroinflammation and disease progression in Parkinson’s disease, with the objective of carrying out a Phase I-II clinical trial.

The consortium brings together leading Nordic academic and clinical institutions including University of Bergen (UiB), Haukeland universitetssjukehus, and Karolinska Institutet, with EXO Biologics contributing its GMP Extracellular Vesicle platform and EV material to support the clinical trial.

The second collaboration, which also include Haukeland universitetssjukehus, focuses on M𝘂𝗹𝘁𝗶𝗽𝗹𝗲 S𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀 (𝗠𝗦) and investigates the intranasal administration of Extracellular Vesicles as a novel therapeutic approach. This project has received NOK 12.8 million in funding (approximately €1.1 million) and also aims to start a phase I trial.

We are proud to collaborate with leading academic partners on these ambitious projects and to contribute to bringing extracellular vesicle therapeutics closer to clinical application.